Published in AIDS on April 24, 2006
Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. J Clin Lipidol (2010) 1.50
Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol (2010) 1.34
HIV and HAART-Associated Dyslipidemia. Open Cardiovasc Med J (2011) 1.34
The nephrotoxic effects of HAART. Nat Rev Nephrol (2009) 1.20
The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab (2009) 1.20
Management of the metabolic effects of HIV and HIV drugs. Nat Rev Endocrinol (2011) 0.97
Statins to improve cardiovascular outcomes in treated HIV infection. Curr Opin Infect Dis (2016) 0.87
New and emerging agents in the management of lipodystrophy in HIV-infected patients. HIV AIDS (Auckl) (2010) 0.83
Effects of randomized rosuvastatin compared with placebo on bone and body composition among HIV-infected adults. AIDS (2015) 0.81
HIV protease inhibitors and obesity. Curr Opin Endocrinol Diabetes Obes (2010) 0.81
The effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patients. PPAR Res (2008) 0.80
Approach to the human immunodeficiency virus-infected patient with lipodystrophy. J Clin Endocrinol Metab (2008) 0.79
Statin therapy and changes in hip circumference among HIV-infected participants in the ALLRT Cohort. Antivir Ther (2009) 0.78
Statins in HIV-associated lipodystrophy and metabolic syndrome: is there a missing link? AIDS (2006) 0.75
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med (2015) 15.06
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33
Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med (2005) 6.49
The case for boosting infant male circumcision in the face of rising heterosexual transmission of HIV. Med J Aust (2010) 5.94
Relation between HIV viral load and infectiousness: a model-based analysis. Lancet (2008) 5.74
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr (2006) 4.71
Monitoring mosquito net coverage for malaria control in Africa: possession vs. use by children under 5 years. Trop Med Int Health (2003) 4.29
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med (2008) 3.71
Identification of new susceptibility loci for osteoarthritis (arcOGEN): a genome-wide association study. Lancet (2012) 3.48
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis (2009) 3.32
The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr (2005) 3.18
Characterization of CD4(+) CTLs ex vivo. J Immunol (2002) 3.10
National malaria control and scaling up for impact: the Zambia experience through 2006. Am J Trop Med Hyg (2008) 3.05
Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial. AIDS (2005) 2.94
Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther (2008) 2.93
HIV prevention research in a resource-limited setting: the experience of planning a trial in Cambodia. Lancet (2005) 2.83
Induction of a hemogenic program in mouse fibroblasts. Cell Stem Cell (2013) 2.71
Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution. J Virol (2006) 2.70
CryptoDB: a Cryptosporidium bioinformatics resource update. Nucleic Acids Res (2006) 2.68
Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A/C-deficient mice. J Clin Invest (2004) 2.67
Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation (2008) 2.64
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS (2007) 2.58
Large-scale analysis of association between GDF5 and FRZB variants and osteoarthritis of the hip, knee, and hand. Arthritis Rheum (2009) 2.47
No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet (2004) 2.43
Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis (2010) 2.41
ApiDB: integrated resources for the apicomplexan bioinformatics resource center. Nucleic Acids Res (2006) 2.37
A pilot study investigating the effects of remote ischemic preconditioning in high-risk cardiac surgery using a randomised controlled double-blind protocol. Basic Res Cardiol (2012) 2.37
Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis (2011) 2.34
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS (2007) 2.27
Pan genome of the phytoplankton Emiliania underpins its global distribution. Nature (2013) 2.26
Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr (2010) 2.26
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med (2009) 2.21
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis (2010) 2.14
Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis (2009) 2.08
The Oxford shoulder score revisited. Arch Orthop Trauma Surg (2008) 2.06
Predictors of disease progression in HIV infection: a review. AIDS Res Ther (2007) 2.05
A genome-wide association study identifies an osteoarthritis susceptibility locus on chromosome 7q22. Arthritis Rheum (2010) 2.02
Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. Lancet Infect Dis (2012) 2.01
Shoulder pain: diagnosis and management in primary care. BMJ (2005) 2.01
Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation (2004) 1.99
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr (2002) 1.98
Electronically assisted nasolacrimal duct silicone intubation. Ophthal Plast Reconstr Surg (2013) 1.98
Mutations in cardiac T-box factor gene TBX20 are associated with diverse cardiac pathologies, including defects of septation and valvulogenesis and cardiomyopathy. Am J Hum Genet (2007) 1.97
HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS (2009) 1.88
Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA (2002) 1.88
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS (2004) 1.85
Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS (2003) 1.80
Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis (2005) 1.80
Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy. J Infect Dis (2009) 1.79
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis (2013) 1.78
Meta-analysis of genome-wide association studies confirms a susceptibility locus for knee osteoarthritis on chromosome 7q22. Ann Rheum Dis (2010) 1.75
The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials (2002) 1.73
VEGFR1/CXCR4-positive progenitor cells modulate local inflammation and augment tissue perfusion by a SDF-1-dependent mechanism. J Mol Med (Berl) (2008) 1.67
Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis (2009) 1.66
Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS (2004) 1.62
Evaluation of the genetic overlap between osteoarthritis with body mass index and height using genome-wide association scan data. Ann Rheum Dis (2012) 1.62
A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis (2005) 1.62
Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS (2004) 1.61
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis (2015) 1.61
Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction. J Infect Dis (2008) 1.60
Effects of granulocyte-colony stimulating factor on chromosome aneuploidy and replication asynchrony in healthy peripheral blood stem cell donors. Blood (2011) 1.60
A variant in MCF2L is associated with osteoarthritis. Am J Hum Genet (2011) 1.60
The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS (2002) 1.59
Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. Circulation (2004) 1.59
Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research. AIDS (2007) 1.53
Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS (2006) 1.52
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology (2008) 1.52
Comparative responsiveness and minimal change for the Oxford Elbow Score following surgery. Qual Life Res (2008) 1.52
Determinants of hanging and use of ITNs in the context of near universal coverage in Zambia. Health Policy Plan (2011) 1.51
Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS (2007) 1.49
Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy. Diabetes (2002) 1.49
Investigating the aspartic acid (D) repeat of asporin as a risk factor for osteoarthritis in a UK Caucasian population. Arthritis Rheum (2005) 1.48
Extreme context specificity in differential allelic expression. Hum Mol Genet (2007) 1.47
Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS (2003) 1.47